Madrigal Pharmaceuticals
Developing novel NASH therapeutics
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for non-alcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Our lead candidate, resmetirom, is a once daily, oral, thyroid hormone receptor (THR)-β selective agonist targeting key causes of NASH. Currently in Phase 3 clinical studies, resmetirom aims to demonstrate multiple benefits for NASH patients. Join our team and contribute to groundbreaking advancements in liver disease treatment.
Benefits of using Remote First Jobs
Discover Hidden Jobs
Unique jobs you won't find on other job boards.
Advanced Filters
Filter by category, benefits, seniority, and more.
Priority Job Alerts
Get timely alerts for new job openings every day.
Manage Your Job Hunt
Save jobs you like and keep a simple list of your applications.
Search remote, work from home, 100% online jobs
We help you connect with top remote-first companies.
Hiring remote talent? Post a job